We further strengthened these data through lentivirus-mediated transduction and DCF fluorescence analysis by flow cytometry using two different sequences to knockdown mutant p53 expression (p53-SH1 or p53-SH2) or their negative control (p53-NT) in breast cancer MDA-MB-231 cells (Fig. 1b). This evidence concerns the gene TP53 and breast cancer.